{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06154252",
            "orgStudyIdInfo": {
                "id": "CAB-201-002"
            },
            "organization": {
                "fullName": "Cabaletta Bio",
                "class": "INDUSTRY"
            },
            "briefTitle": "RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy",
            "officialTitle": "A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy",
            "therapeuticArea": [
                "Rare Diseases",
                "Immunology and Rheumatology",
                "Other"
            ],
            "study": "reset-myositis-an-open-label-study-to-evaluate-the-safety-and-efficacy-of-caba-in-subjects-with-active-idiopathic-inflammatory-myopathy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-16",
            "studyFirstSubmitQcDate": "2023-11-30",
            "studyFirstPostDateStruct": {
                "date": "2023-12-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Cabaletta Bio",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy",
            "detailedDescription": "Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, and IMNM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated."
        },
        "conditionsModule": {
            "conditions": [
                "Idiopathic Inflammatory Myopathy",
                "Dermatomyositis",
                "Anti-Synthetase Syndrome",
                "Immune-Mediated Necrotizing Myopathy"
            ],
            "keywords": [
                "CABA-201",
                "Autoimmune Disease",
                "Anti-CD19 CAR-T therapy",
                "Cellular Therapy",
                "Idiopathic Inflammatory Myopathy",
                "Myositis",
                "Dermatomyositis",
                "Anti-synthetase Syndrome",
                "Immune-mediated Necrotizing Myopathy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 18,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CABA-201",
                    "type": "EXPERIMENTAL",
                    "description": "DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with DM ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with ASyS IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with IMNM",
                    "interventionNames": [
                        "Biological: CABA-201 following preconditioning with fludarabine and cyclophosphamide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "CABA-201 following preconditioning with fludarabine and cyclophosphamide",
                    "description": "Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide",
                    "armGroupLabels": [
                        "CABA-201"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "To evaluate adverse events reported by subjects",
                    "description": "Incidence and severity of AEs",
                    "timeFrame": "Up to 28 days after CABA-201 infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To evaluate adverse events and laboratory abnormalities",
                    "description": "Incidence and severity of AEs, including changes in laboratory values and vital signs",
                    "timeFrame": "Up to 156 weeks"
                },
                {
                    "measure": "To characterize the pharmacodynamics (PD)",
                    "description": "Levels of B cells in the blood",
                    "timeFrame": "Up to 156 weeks"
                },
                {
                    "measure": "To characterize the pharmacokinetics (PK)",
                    "description": "Levels of CABA-201-positive T cells in the blood",
                    "timeFrame": "Up to 156 weeks"
                },
                {
                    "measure": "To evaluate disease-related biomarkers of muscle inflammation",
                    "description": "Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum",
                    "timeFrame": "Up to 156 weeks"
                },
                {
                    "measure": "To evaluate autoantibody -related biomarkers",
                    "description": "Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum",
                    "timeFrame": "Up to 156 Weeks"
                },
                {
                    "measure": "To evaluate efficacy",
                    "description": "Total Improvement Score (0 to 100, with higher scores indicating greater improvement) based on the Core Set Measures",
                    "timeFrame": "Up to 156 Weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u226518 and \u226465\n* A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria\n* Diagnosis of DM, ASyS, IMNM based on the presence of serum myositis-specific antibodies\n* Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography\n* Presence of muscle weakness\n\nExclusion Criteria:\n\n* Contraindication to leukapheresis\n* History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites\n* Active infection requiring medical intervention at screening\n* Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.\n* Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures\n* Significant lung or cardiac impairment\n* Previous CAR T cell therapy\n* Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Cabaletta Bio",
                    "role": "CONTACT",
                    "phone": "12677593100",
                    "phoneExt": "4444",
                    "email": "clinicaltrials@cabalettabio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Cabaletta Bio",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California Irvine",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alpha Clinic",
                            "role": "CONTACT",
                            "phone": "949-824-3990",
                            "email": "alphaclinic@uci.edu"
                        },
                        {
                            "name": "Tahseen Mozaffar, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "University of Kansas Medical Center",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Kansas",
                    "zip": "66160",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ali Russo, B.S., CCRP",
                            "role": "CONTACT",
                            "phone": "913-945-9942",
                            "email": "aciersdorff@kumc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.11417,
                        "lon": -94.62746
                    }
                },
                {
                    "facility": "Mayo Clinic",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55902",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Izzie Meunier",
                            "role": "CONTACT",
                            "phone": "507-538-6337",
                            "email": "Meunier.Isabelle@mayo.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Oregon Health & Science University",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Katie Lewis",
                            "role": "CONTACT",
                            "phone": "503-908-9724",
                            "email": "lewiskat@ohsu.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Vanderbilt University Medical Center",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37232",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pamela Krueger",
                            "role": "CONTACT",
                            "phone": "615-875-8356",
                            "email": "pamela.krueger@vumc.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christine Griesmer",
                            "role": "CONTACT",
                            "phone": "832-846-0218",
                            "email": "clgriesmer@mdanderson.org"
                        },
                        {
                            "name": "Huifang (Linda) Lu, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D000003882",
                    "term": "Dermatomyositis"
                },
                {
                    "id": "D000009220",
                    "term": "Myositis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000017285",
                    "term": "Polymyositis"
                },
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "asFound": "Myopathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12172",
                    "name": "Myositis",
                    "asFound": "Idiopathic Inflammatory Myopathies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7077",
                    "name": "Dermatomyositis",
                    "asFound": "Dermatomyositis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19579",
                    "name": "Polymyositis",
                    "relevance": "LOW"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3040",
                    "name": "Inclusion Body Myositis",
                    "asFound": "Inflammatory Myopathies",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3001",
                    "name": "Idiopathic Inflammatory Myopathy",
                    "asFound": "Idiopathic Inflammatory Myopathies",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1814",
                    "name": "Dermatomyositis",
                    "asFound": "Dermatomyositis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4054",
                    "name": "Necrotizing Autoimmune Myopathy",
                    "asFound": "Immune-Mediated Necrotizing Myopathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T439",
                    "name": "Antisynthetase Syndrome",
                    "asFound": "Anti-synthetase Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4623",
                    "name": "Polymyositis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}